Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

The Lancet. Oncology - 1 Jul 2011

Jordheim Lars Petter, Sève Pascal, Trédan Olivier, Dumontet Charles

Abstract excerpt

The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of cell proliferation, cell migration, tumour and metastasis development, and the synthesis of deoxyribonucleotides for DNA synthesis. It is also a cellular target for the chemotherapeutic agent, gemcitabine. RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to RRM1 gene
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Ribonucleoside Diphosphate Reductase

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 21163702
DOI: 10.1016/S1470-2045(10)70244-8

Genes

RRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.PMID 21163702Read ↗

Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature‐based meta‐analysisSemantic proximity Read ↗

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Semantic proximity Read ↗

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.Semantic proximity Read ↗

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancerSemantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumorsSemantic proximity Read ↗

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.Semantic proximity Read ↗

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and PresentSemantic proximity Read ↗

MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cellsSemantic proximity Read ↗

RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients.Semantic proximity Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.